Alternative Blog Styles

You are currently browsing the Eye on the Cure blog archives for June, 2012.



Meet Dr. Steve Rose

Dr. Steve RoseSteve is highly respected for his expertise and tireless commitment to finding treatments and cures for vision-robbing retinal diseases.

Dr. Steve Rose 

Newsletter Sign Up

*  
*  
*  
*  


   Please leave this field empty

Archive for June, 2012

Getting Personal at VISIONS 2012

28Jun

Video Included:
John Corneille at VISIONS 2012
I work for FFB, as its director of gift planning, but I also actually have a retinal disease – something called retinitis pigmentosa, or RP. Although I was diagnosed at age 5, I didn’t discover I had RP till I was 18, partly because my parents didn’t want the disease to hold me back in any way.
Read more

Video Included:
Hyatt Staff experiences sensitivity training
In preparation for the arrival of VISIONS 2012 attendees, we did what we usually do the day prior – provided hotel staff, everyone from housekeepers to food servers to managers, with blind-sensitivity training.

Read more

Every year, in late June, the Foundation Fighting Blindness hosts an annual conference we call – for, perhaps, obvious reasons – VISIONS. It’s a four-day event during which FFB members, staff, board members, trustees and retinal experts gather under one roof to focus on those things we do best.
Read more

In the lab with beakerIt seems there is no dearth of fantastic cures being touted on the Internet and in email inboxes these days. Sort of reminds me of those old Western movies where the itinerant peddler sells the magic elixir that will cure any and all ailments you have. Read more

Rod cells derived from iPSC at the RIKEN labs.I just learned some promising news from the stem cell research front. RIKEN, an innovative research group in Japan, is hoping to launch a clinical trial of an age-related macular degeneration (AMD) treatment derived from induced pluripotent stem cells (iPSC). Based on my current knowledge, this would be the first-ever iPSC-based treatment for the retina to move into a human study.
Read more